Corneal Endothelial Cell Loss in Patients After Minimally Invasive Glaucoma Surgery: Current Perspectives
,Iwona Obuchowska,Joanna Konopińska
DOI: https://doi.org/10.2147/OPTH.S359305
2022-05-25
Clinical Ophthalmology
Abstract:Iwona Obuchowska, Joanna Konopi&nacuteska Department of Ophthalmology, Medical University of Bialystok, Bialystok, 15-276, Poland Correspondence: Joanna Konopi&nacuteska, Department of Ophthalmology, Medical University of Bia&lstrokystok, M. Sklodowska-Curie 24A STR, Bia&lstrokystok, 15-276, Poland, Tel/Fax +48 857468372, Email Minimally invasive glaucoma surgery (MIGS) is a rapidly expanding category of surgical glaucoma treatment options that offer a superior safety profile compared with traditional approaches for reducing intraocular pressure. However, MIGS may cause corneal endothelial cell loss; therefore, it has been receiving increasing attention. This systematic review aimed to evaluate and compare the rate and degree of corneal endothelial loss after MIGS. First, this paper presents an overview of the theoretical effectiveness of MIGS, the fundamental aspects regarding the roles of endothelial cells, and the effect of cataract surgery on the quality and count of endothelial cells. Further, we detail the various surgical techniques involved in MIGS, the development of these techniques over the time, and clinical aspects to consider with respect to the endothelial cell count. We discuss in detail the COMPASS-XT study, which was based on data collected over 5 years, reported that withdrawal of the CyPass Micro-Stent (Alcon Laboratories) yielded increased corneal endothelial cell loss. Generally, MIGS procedures are considered safe, with the incidence of complications ranging from 1% to 20% depending on the surgery type; however, there is still need for studies with longer follow-up. Thus, an adequate count of endothelial cells in the central cornea portion is recommended as necessary for candidate patients for MIGS. Keywords: minimally invasive glaucoma surgery, endothelial cell loss, corneal decompensation, glaucoma surgery Worldwide, glaucoma is a primary cause of irreversible blindness and is treated by decreasing the intraocular pressure (IOP) to prevent glaucomatous optic neuropathy (GON). Although it remains possible to effectively control IOP with glaucoma eye drops in many patients, for some of them only effective treatment remains glaucoma surgery. (eg, non-compliance with medical recommendations, allergy to eye drops treatment costs. However, topical drop therapy often involves poor adherence (incidence rate: 5–80%), with independent risk factors including lack of education regarding the risk of irreversible vision loss. Moreover, complex dosing regimens involving one or more medications place high demands on patients' daily routines. Furthermore, the chronic use of glaucoma drops, especially those containing preservative agents, is associated with an increased incidence of meibomian gland dysfunction and ocular surface toxicity. Additionally, daily use of topical drops can cause symptoms of burning, photophobia, and irritation. Taken together, these factors promote the discontinuation of or intolerance to the prescribed therapy. 1,2 For these reasons, glaucoma surgery is the only effective treatment alternative for some patients. Despite considered very effective, classical incision surgical glaucoma procedures, including trabeculectomy, glaucoma shunt implantation (Ex-PRESS), and glaucoma valve implantation (Ahmed, Molteno, Baerveldt), cannot be used in place of pharmacotherapy, thus involve a risk of vision-threatening complications. However, these limitations have been mitigated with the advent of minimally invasive glaucoma surgeries (MIGS). 3,4 MIGS seek to decrease the IOP and number of administered glaucoma eye medications with minimal invasiveness and maximal safety manner. This can be achieved by avoiding conjunctival incisions; moreover, this procedure is traditionally performed using an ab interno approach and a clear corneal incision, which results in fewer complications and a relatively short recovery period. Safety and effectiveness are the critical factors to account for when considering MIGS. In many cases, MIGS are combined with phacoemulsification, which further reduces the IOP. Since MIGS cannot extensively reduce the IOP as traditional incisional glaucoma surgery, they are mainly used for patients with mild-to-moderate glaucoma. 5,6 Specifically, MIGS are usually used to treat open-angle glaucoma (OAG), including primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PXG), and pigmentary glaucoma (PG). Additionally, there have been some papers of MIGS that have been used for primary angle-closure glaucoma (PACG), normal-tension glaucoma (NTG), and uveitic glaucoma; however, minimally invasive procedures are not routinely considered for these glaucoma types. 6 The incidence of complications depends on the type of surgical technique and ranges from 1% to 20%, with an approximate average of 3 -Abstract Truncated-